Qu Biologics.png
Positive Signals for Endoscopic and Histologic Response in Patients with Crohn’s Disease Treated with Qu Biologics’ QBECO
January 04, 2021 09:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
Kenneth Rainin Foundation Announces Earlier Funding For Innovator Awards
September 15, 2020 10:55 ET | Kenneth Rainin Foundation
Oakland, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation announced today that it will open its annual Innovator Awards early to meet researcher needs. The program supports...
Surrozen Logo FINAL Large-1.png
UPDATE -- Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials
June 19, 2020 10:00 ET | Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the successful...
Surrozen Logo FINAL Large-1.png
Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials
June 19, 2020 07:00 ET | Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the successful...
Innovation Pharmaceuticals Plans for Phase 2 Trial of New Treatment for Ulcerative Colitis
March 05, 2020 08:00 ET | Innovation Pharmaceuticals Inc.
Active ulcerative colitis targeted; multiple ascending dose design (low, mid, high doses and placebo)Endpoints: clinical remission (Mayo scoring); endoscopic remission; biomarkers, and others ...
PAVMEDLOGONEW15OCT2018.png
PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients
March 02, 2020 09:30 ET | PAVmed Inc.
Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires multiple and...
Innovation Pharmaceuticals Completes Dosing in Phase 1 Trial for New Oral Ulcerative Colitis Drug
January 24, 2020 11:30 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., Jan. 24, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today the Company completed dosing in...
Innovation Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Topline Results Anticipated Early Q1 2020
January 16, 2020 12:00 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders that the...
Grant Opportunity To Improve Prediction And Prevention Of IBD
January 07, 2020 10:55 ET | Kenneth Rainin Foundation
Oakland, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation invites Letters of Inquiry for its Innovator Awards Program from January 15 through February 18, 2020. The program...
Kenneth Rainin Foundation Awards Over $2 Million To Advance IBD Research
October 22, 2019 10:55 ET | Kenneth Rainin Foundation
Oakland, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation has awarded $2.2 million through its Innovator Awards to advance Inflammatory Bowel Disease (IBD) research and...